PhageVax, Inc. is a pioneering biotech company based in Newark, OH, specializing in the development of innovative vaccine technologies. Their groundbreaking research focuses on the creation of a needle-free mucosal COVID-19 vaccine, based on bacteriophage T4, which has shown promising results in inducing strong immune responses and offering complete protection in animal models. This novel vaccine remains stable at ambient temperature, addressing a significant challenge in vaccine distribution and storage. PhageVax, Inc. is dedicated to advancing their world-class nasal spray vaccine technology and aims to provide both prevention and therapeutic solutions for COVID-19 and other diseases.
Generated from the website